Jiménez-Segura, Raquel
Rosiñol, Laura http://orcid.org/0000-0002-2534-9239
Cibeira, Ma Teresa
Fernández de Larrea, Carlos http://orcid.org/0000-0003-4930-9255
Tovar, Natalia
Rodríguez-Lobato, Luis Gerardo http://orcid.org/0000-0001-5694-0921
Bladé, Esther
Moreno, David F.
Oliver-Caldés, Aina http://orcid.org/0000-0002-7921-5420
Bladé, Joan http://orcid.org/0000-0002-4563-3405
Article History
Received: 24 May 2022
Revised: 23 August 2022
Accepted: 31 August 2022
First Online: 16 September 2022
Competing interests
: LR received honoraria for lectures and advisory boards from Janssen, Celgene/BMS, Amgen, Takeda, GSK and Sanofi. MTC received honoraria for lectures and advisory boards from Janssen, Amgen and Akcea. CFdL received honoraria for lectures from Janssen, Celgene/BMS, Amgen, Pfizer, GSK, and Sanofi and research funding from Janssen, Celgene/BMD, Amgen and Takeda. LGRL received honoraria for lectures from Janssen and Amgen. JB received honoraria for lectures from Janssen, Celgene/BMS, Amgen, Takeda, Oncopeptides. The remaining authors declare no competing interests.